Biophytis (BPTSY) AI Stock Analysis

Biophytis

(Other OTC:BPTSY)

Select Model

Rating:41Neutral

Price Target:$0.80▲(168.69% Upside)

Action:upgraded

Date:12/30/25

The score is primarily held down by weak financial performance (no revenue, ongoing cash burn, and negative equity), reinforced by bearish technicals with the stock trading below major moving averages. Valuation is also constrained by negative earnings and no dividend support, with only a minor offset from oversold momentum readings.

Positive Factors

Focused clinical-stage pipelineBiophytis is a clinical-stage biotech focused on age-related diseases with a clear lead program (Sarconeos/BIO101). A focused R&D portfolio concentrates resources on a single high-value indication, preserving capital and management attention to advance trials and partner/licence outcomes.

Negative Factors

No revenue / no commercial productBiophytis has no product revenues and remains pre-commercial, meaning its long-term viability depends on clinical/regulatory success or partnerships. This structural absence of recurring revenue increases execution risk and prolongs reliance on external funding to sustain operations.

Biophytis (BPTSY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $105.22K
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.0
Beta (1Y): 0.64
Revenue Growth: ―
EPS Growth: 90.80%
Country: US
Employees: 19
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Biophytis Business Overview & Revenue Model

Company Description

Biophytis S.A. is a clinical-stage biotechnology firm dedicated to developing therapeutic interventions that slow the degenerative processes associated with age and improve functional outcomes for patients. The company's innovative treatments work by...

How the Company Makes Money

Biophytis does not have a recurring product-revenue base because it is a clinical-stage biotech and, as of the latest publicly available information, it has not commercialized an approved drug. As a result, the company’s cash inflows typically come f...

Biophytis Financial Statement Overview

Summary

No revenue and continued losses/cash burn keep fundamentals weak. While 2024 losses and operating cash outflow improved versus 2023, the balance sheet is fragile with negative equity and higher debt, increasing dependence on external financing.

Income Statement

12Very Negative

Balance Sheet

9Very Negative

Cash Flow

14Very Negative

Financial statement breakdown
Breakdown	TTM	Jun 2025	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0	0	0	0	0	0
Gross Profit	0	0	-803.00K	―	-311.00K	-280.00K
EBITDA	-8.20M	-8.20M	-13.53M	-22.79M	-26.50M	-13.66M
Net Income	-10.38M	-10.38M	-17.03M	-24.22M	-31.16M	-25.52M
Balance Sheet
Total Assets	6.90M	6.90M	11.96M	21.99M	34.87M	27.21M
Cash, Cash Equivalents and Short-Term Investments	78.00K	78.00K	5.93M	11.05M	25.16M	18.77M
Total Debt	9.84M	9.84M	8.27M	12.13M	16.65M	15.05M
Total Liabilities	16.60M	16.60M	15.85M	23.90M	29.07M	24.94M
Stockholders Equity	-9.67M	-9.67M	-3.86M	-1.88M	5.83M	2.30M
Cash Flow
Free Cash Flow	-8.64M	-8.64M	-13.09M	-19.13M	-24.14M	-10.08M
Operating Cash Flow	-8.64M	-8.64M	-12.87M	-18.99M	-23.80M	-9.86M
Investing Cash Flow	19.84M	10.00K	370.00K	-17.00K	12.16M	-12.71M
Financing Cash Flow	551.96M	3.14M	7.03M	6.13M	29.71M	21.95M

Biophytis Technical Analysis

Technical Analysis SentimentNegative

Last Price0.30

Price Trends

50DMA0.30Negative

100DMA0.30Positive

200DMA0.37Negative

Market Momentum

MACD-0.00Negative

RSI21.87Positive

STOCH-0.00Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTSY, the sentiment is Negative. The current price of 0.30 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.30, and below the 200-day MA of 0.37, indicating a neutral trend. The MACD of -0.00 indicates Negative momentum. The RSI at 21.87 is Positive, neither overbought nor oversold. The STOCH value of -0.00 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTSY.

Biophytis Risk Analysis

Biophytis disclosed 71 risk factors in its most recent earnings report. Biophytis reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Our drug candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or authorization, limit the commercial profile of an approved or authorized label, or result in significant negative consequences following marketing approval or authorization, if any.Q4, 2023

2.A resurgence of COVID-19 (or emergence of new vaccine resistant strains), pandemic, endemic, or emergence of other infectious disease, may limit our ability or the investigators' ability to find and retain medical staffs that are needed to conduct the clinical studies.Q4, 2023

Biophytis Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

BPTSY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
INM	48Neutral	$8.79M	-0.46	-134.73%	―	-60.74%	66.05%
BPTSY	41Neutral	$12.90M	-0.01	153.48%	―	―	90.80%
ONCO	33Underperform	$3.30M	-0.06	-91.95%	―	-51.33%	99.22%

* Healthcare Sector Average

Performance Comparison

BPTSY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
BPTSY	Biophytis Sa	0.30	-0.93	-75.77%
OGEN	Oragenics Inc	0.37	-0.85	-69.34%
INM	Inmed Pharmaceuticals Inc.	1.60	-0.25	-13.51%
KTTA	Pasithea Therapeutics Corp.	0.37	-0.45	-54.88%
SPRC	SciSparc Ltd.	0.68	-29.20	-97.74%
ONCO	Onconetix Inc	0.56	-157.44	-99.64%

Biophytis Corporate Events

Biophytis Strikes Asia Joint Venture and Secures $20 Million to Fund Phase 3 Sarcopenia Trial

Jan 28, 2026

On January 28, 2026, Biophytis announced it had signed a landmark agreement to create a Hong Kong-based joint venture, Biophytis Biopharmaceutical Holding LTD, with a consortium of Asian partners led by China’s Ronghui Renhe Life Technology, to...

Biophytis Announces Approval of Resolutions at General Meeting

Nov 14, 2025

On November 13, 2025, Biophytis announced that all resolutions proposed during their Combined General Meeting were approved, including the financial statements for the fiscal year 2024. This approval, achieved with a shareholder quorum of nearly 31%,...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 30, 2025

Biophytis AI Stock Analysis